Mark H Bruner

US Patent:

7927870, Apr 19, 2011

Filed:

May 10, 2006

Appl. No.:

11/431676

Inventors:

David B. Volkin - Doylestown PA, US
Robert K. Evans - Soudertown PA, US
Mark Bruner - Norristown PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C12N 15/00
C07H 21/04

US Classification:

4353201, 536 231

Abstract:

This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.

US Patent:

20020156037, Oct 24, 2002

Filed:

Sep 7, 2001

Appl. No.:

09/948337

Inventors:

David Volkin - Doylestown PA, US
Robert Evans - Soudertown PA, US
Mark Bruner - Norristown PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K048/00
C07H021/04

US Classification:

514/044000, 536/023100, 536/025400

Abstract:

This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.

US Patent:

20040138165, Jul 15, 2004

Filed:

Oct 30, 2003

Appl. No.:

10/697233

Inventors:

David Volkin - Doylestown PA, US
Robert Evans - Soudertown PA, US
Mark Bruner - Norristown PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K048/00
C07H021/04

US Classification:

514/044000, 536/025400

Abstract:

This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.

US Patent:

6387695, May 14, 2002

Filed:

Dec 22, 1998

Appl. No.:

09/218590

Inventors:

Robert K. Evans - Souderton PA
David B. Volkin - Doylestown PA
Mark W. Bruner - Norristown PA
Zheng Xu - Blue Bell PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C12N 1588

US Classification:

4353201, 435 691, 435325, 435455

Abstract:

The present invention relates to nucleic acid formulations of pharmaceutical products which comprise citrate and/or triethanolamine in concentrations which enhance stability of the nucleic acid. These formulations are suited for situations where prolonged storage occurs during the distribution and/or storage period prior to use.

US Patent:

20190202870, Jul 4, 2019

Filed:

Mar 20, 2019

Appl. No.:

16/358928

Inventors:

- Leiden, NL
Mark BRUNER - Norristown PA, US

International Classification:

C07K 14/005
C12N 15/09
C07K 14/16
A61K 33/06
A61K 39/38
A61K 39/21
A61K 39/12

Abstract:

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.

US Patent:

20170362280, Dec 21, 2017

Filed:

Jun 15, 2017

Appl. No.:

15/623684

Inventors:

- Leiden NL, US
Mark BRUNER - Norristown PA, US

International Classification:

C07K 14/005
A61K 39/21
C12N 15/09
A61K 39/38
A61K 39/12
C07K 14/16
A61K 39/00

Abstract:

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.